Safety and pharmacokinetics of quizartinib in Japanese patients with relapsed or refractory acute myeloid leukemia in a phase 1 study

导出原文传递

翻译打印收藏纠错

作者： Usuki, Kensuke ^[1] ; Handa, Hiroshi ^[2] ; Choi, Ilseung ^[3] ; Yamauchi, Takahiro ^[4] ; Iida, Hiroatsu ^[5] ; Hata, Tomoko ^[6] ; Ohwada, Shoichi ^[7] ; Okudaira, Noriko ^[8] ; Nakamura, Kota ; Sakajiri, Sakura

作者单位： Nagasaki Univ Hosp, Nagasaki, Japan ^[1] Kyushu Canc Ctr, Natl Hosp Org, Fukuoka, Japan ^[2] Univ Fukui Hosp, Fukui, Japan ^[3] Gunma Univ Hosp, Maebashi, Gumma, Japan ^[4] Juntendo Univ, Urayasu Hosp, Urayasu, Japan ^[5] Nagoya Med Ctr, Natl Hosp Org, Nagoya, Aichi, Japan ^[6] NTT Med Ctr Tokyo, Shinagawa Ku, 5-9-22 Higashi Gotanda, Tokyo 1418625, Japan ^[7] Daiichi Sankyo Co Ltd, Tokyo, Japan ^[8]

关键词 FLT3 inhibitor Japan Phase 1 Quizartinib Relapsed or refractory acute myeloid leukemia

发布时间 2020-04-25

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交